Mochida Pharmaceutical Co., Ltd.
Notice regarding the status of share buyback
The acquisition target is common stock, total number of shares acquired is 90,600 shares, total acquisition value is 286,404,500 yen (286,404,500 yen), and the acquisition period is from 2026/7/1 to 2026/7/31, with the method being market purchases. Cumulative to date is 186,500 shares, total value 603,565,000 yen.
Key Figures
- Total number of shares acquired: 90,600 shares
- Total acquisition value: 286,404,500 yen
- Acquisition period: July 1, 2026 to July 31, 2026
- Cumulative shares acquired: 186,500 shares
- Cumulative acquisition value: 603,565,000 yen
AI要約
Transaction overview
This notice published today reports the status of share buyback conducted by Holdin Pharmaceutical Co., Ltd. The target shares are the company's common stock, with this acquisition consisting of 90,600 shares for a total of 286,404,500 yen. The acquisition period is from July 1, 2026 to July 31, 2026 on an execution basis, and the method is market purchases on the Tokyo Stock Exchange. Note that at the board meeting held on March 30, 2026, an upper limit of 530,000 shares (1.5% of issued shares) and a total amount of 2,000,000,000 yen were approved; to date, cumulative shares acquired are 186,500 with a total of 603,565,000 yen.
Impact on shareholders and future outlook
The notice states that share buyback is subject to market conditions, and purchases may continue or be halted depending on circumstances. The cumulative acquisition is based on market purchases and is presented as part of shareholder value enhancement and capital policy. Currently, progress relative to the upper limit is limited, but additional buyback plans may be disclosed in the future.
Holden Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
